Marrone Bio Innovations Inc (NASDAQ:MBII) (FRA:0MB) shares climbed Friday after an analyst at Canaccord Genuity upped the price target for the company to $3.50 from $2 and reiterated a Buy rating.  The company introduced a 2022 revenue projection of $7.7 million based on “a continuing shift to seed and soil treatme
Full Story >>
Vote
+14